We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Inhibrx Biosciences Inc | NASDAQ:INBX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.30 | 2.23% | 13.73 | 12.85 | 14.45 | 13.79 | 13.26 | 13.53 | 25,072 | 21:00:04 |
As filed with the Securities and Exchange Commission on March 6, 2023 | |||||||||||||||||
REGISTRATION NO. 333 - | |||||||||||||||||
UNITED STATES | |||||||||||||||||
SECURITIES AND EXCHANGE COMMISSION | |||||||||||||||||
WASHINGTON, D.C. 20549 | |||||||||||||||||
FORM S-8 | |||||||||||||||||
REGISTRATION STATEMENT UNDER | |||||||||||||||||
THE SECURITIES ACT OF 1933 | |||||||||||||||||
INHIBRX, INC. | ||||||||
(Exact name of registrant as specified in its charter) | ||||||||
Delaware | 82-4257312 | |||||||
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |||||||
11025 N. Torrey Pines Road, Suite 200 | ||||||||
La Jolla, California | 92037 | |||||||
(Address of principal executive offices) | (Zip Code) | |||||||
(858) 795-4220 | ||||||||
(Registrant’s telephone number, including area code) | ||||||||
Inhibrx, Inc. Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan | ||||||||
(Full Title of the Plan) | ||||||||
Mark Lappe | ||||||||
Chief Executive Officer | ||||||||
Inhibrx, Inc. | ||||||||
11025 N. Torrey Pines Road, Suite 200 | ||||||||
La Jolla, CA 92037 | ||||||||
(858) 795-4220 | ||||||||
(Name, Address, and Telephone Number, Including Area Code, of Agent For Service) | ||||||||
Copies to: | ||||||||
Jeremy Glaser | ||||||||
Melanie Ruthrauff Levy | ||||||||
Mintz, Levin, Cohn, Ferris, Glovsky & | ||||||||
Popeo, P.C. | ||||||||
3580 Carmel Mountain Road, Suite 300 | ||||||||
San Diego, CA 92130 | ||||||||
(858) 314-1500 | ||||||||
Large accelerated filer ☐ | Accelerated filer ☐ | ||||
Non-accelerated filer ☒ | Smaller reporting company ☒ | ||||
Emerging growth company ☐ |
Exhibit Number | Exhibit Description | Filed Herewith | Form | Incorporated By Reference File No. | Date Filed | |||||||||||||||||||||||||||
3.1 | 8-K | 001-39452 | 8/21/2020 | |||||||||||||||||||||||||||||
3.2 | 8-K | 001-39452 | 8/21/2020 | |||||||||||||||||||||||||||||
4.1 | S-1 | 333-231907 | 6/3/2019 | |||||||||||||||||||||||||||||
5.1 | X | |||||||||||||||||||||||||||||||
23.1 | X |
23.2 | X | |||||||||||||||||||||||||||||||
24.1 | X | |||||||||||||||||||||||||||||||
99.1Δ | S-1/A | 333-240135 | 8/12/2020 | |||||||||||||||||||||||||||||
99.2Δ | S-1 | 333-231907 | 6/3/2019 | |||||||||||||||||||||||||||||
99.3Δ | S-1 | 333-231907 | 6/3/2019 | |||||||||||||||||||||||||||||
107 | X |
Δ | Management Compensation Plan or arrangement. |
INHIBRX, INC. | |||||
/s/ Mark P. Lappe | |||||
Name: Mark P. Lappe | |||||
Title: Chief Executive Officer and Chairman |
Signature | Title | Date | ||||||||||||
/s/ Mark P. Lappe | Chief Executive Officer and Chairman (principal executive officer) | March 6, 2023 | ||||||||||||
Mark P. Lappe | ||||||||||||||
/s/ Kelly D. Deck, C.P.A. | Chief Financial Officer (principal financial officer and principal accounting officer) | March 6, 2023 | ||||||||||||
Kelly D. Deck, C.P.A. | ||||||||||||||
/s/ Jon Faiz Kayyem, Ph.D. | Director | March 6, 2023 | ||||||||||||
Jon Faiz Kayyem, Ph.D. | ||||||||||||||
/s/ Douglas G. Forsyth | Director | March 6, 2023 | ||||||||||||
Douglas G. Forsyth | ||||||||||||||
/s/ Kimberly Manhard | Director | March 6, 2023 | ||||||||||||
Kimberly Manhard | ||||||||||||||
/s/ Kristiina Vuori, M.D., Ph.D. | Director | March 6, 2023 | ||||||||||||
Kristiina Vuori, M.D., Ph.D. |
1 Year Inhibrx Biosciences Chart |
1 Month Inhibrx Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions